Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Core Points - Cellectis, a clinical-stage biotechnology company, will report its financial results for Q3 2024 on November 4, 2024, after the US market closes [1] - An investor conference call and webcast will take place on November 5, 2024, at 8:00 AM ET, discussing the Q3 results and business updates [2] - Cellectis specializes in gene-editing technologies, particularly in developing CAR-T immunotherapies and therapeutic gene editing for various diseases [2] Company Overview - Cellectis utilizes an allogeneic approach for CAR-T immunotherapies, focusing on off-the-shelf gene-edited CAR T-cells for cancer treatment [2] - The company has 25 years of experience in gene editing and employs TALEN® technology and PulseAgile electroporation system [2] - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, and is listed on Nasdaq and Euronext Growth [2]